NCT06625515View on ClinicalTrials.gov

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions
Advanced Solid TumorsBreast Cancer RecurrentColorectal Cancer MetastaticColon CancerRectal AdenocarcinomaEndometrial Cancer
Interventions
DRUG

ATX-559

DHX9 tablets will be taken orally

Trial Locations (5)

37203

RECRUITING

SCRI Oncology Partners, Nashville

73104

RECRUITING

Stephenson Cancer Center at OU Medicine, Oklahoma City

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

80045

RECRUITING

University of Colorado Cancer Center - Anschutz Medical Campus,, Aurora

Sponsors
All Listed Sponsors
lead

Accent Therapeutics

INDUSTRY